Literature DB >> 31036383

Therapeutic options after surgical failure in Cushing's disease: A critical review.

German Rubinstein1, Andrea Osswald1, Stephanie Zopp1, Katrin Ritzel1, Marily Theodoropoulou1, Felix Beuschlein2, Martin Reincke3.   

Abstract

Cushing's disease (CD) is the most common etiology of Cushing's syndrome (CD) due to corticotroph pituitary adenoma, which are in most cases small (80-90% microadenomas) and in about 40% cannot be visualized on imaging of the sella. First-line treatment for CD is transsphenoidal surgery (TSS) with the aim of complete adenoma removal and preservation of pituitary gland function. As complete adenoma resection is not always possible, surgical failure is a common problem. This can be the case either due to persistent hypercortisolism after first TSS or recurrence of hypercortisolism after initially achieving remission. For these scenarios exist several therapeutic options with their inherent characteristics, which will be covered by this review.
Copyright © 2019. Published by Elsevier Ltd.

Entities:  

Keywords:  ACTH; adrenal steroidogenesis inhibitor; bilateral adrenalectomy; hypercortisolism; pituitary radiation; transsphenoidal surgery

Year:  2019        PMID: 31036383     DOI: 10.1016/j.beem.2019.04.004

Source DB:  PubMed          Journal:  Best Pract Res Clin Endocrinol Metab        ISSN: 1521-690X            Impact factor:   4.690


  4 in total

1.  Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations.

Authors:  Martin Reincke; Adriana Albani; Guillaume Assie; Irina Bancos; Thierry Brue; Michael Buchfelder; Olivier Chabre; Filippo Ceccato; Andrea Daniele; Mario Detomas; Guido Di Dalmazi; Atanaska Elenkova; James Findling; Ashley B Grossman; Celso E Gomez-Sanchez; Anthony P Heaney; Juergen Honegger; Niki Karavitaki; Andre Lacroix; Edward R Laws; Marco Losa; Masanori Murakami; John Newell-Price; Francesca Pecori Giraldi; Luis G Pérez-Rivas; Rosario Pivonello; William E Rainey; Silviu Sbiera; Jochen Schopohl; Constantine A Stratakis; Marily Theodoropoulou; Elisabeth F C van Rossum; Elena Valassi; Sabina Zacharieva; German Rubinstein; Katrin Ritzel
Journal:  Eur J Endocrinol       Date:  2021-03       Impact factor: 6.664

2.  Remission in Cushing's disease is predicted by cortisol burden and its withdrawal following pituitary surgery.

Authors:  A Dutta; N Gupta; R Walia; A Bhansali; P Dutta; S K Bhadada; R Pivonello; C K Ahuja; S Dhandapani; A Hajela; C Simeoli; N Sachdeva; U N Saikia
Journal:  J Endocrinol Invest       Date:  2021-01-16       Impact factor: 4.256

3.  Update in Cushing disease: What the neurosurgeon has to KNOW, on behalf of the EANS skull base section.

Authors:  Sayoa Eulate-Beramendi; Ainhoa Casajús; Lola Ollero; Lynnette K Niemann; Juan Carlos Fernández-Miranda; Michaël Bruneau; Moncef Berhouma; Luigi Maria Cavallo; Jan Frederick Cornelius; Roy T Daniel; Sebastien Froelich; Emmanuel Jouanneau; Ekkehard Kasper; Diego Mazzatenta; Torstein R Meling; Mahmoud Messerer; Henry W S Schroeder; Marcos Tatagiba; Massimiliano Visocchi; Eduard H Voormolen; Idoya Zazpe
Journal:  Brain Spine       Date:  2022-08-07

4.  Cushing's Disease as a Result of Two ACTH-Secreting Pituitary Tumors.

Authors:  Christine Mathai; Jonathan Anolik
Journal:  AACE Clin Case Rep       Date:  2020-12-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.